The objectives are:
1. Evaluation of current available models and their respective usage in various basic studies and drug assessment. Each presenter to perform a SWAT/comparative analysis of the models they present.
2. Discussion on features needed for an ideal model for assessing agent(s) with curative potential
3. Gap analysis and roadmap for developing models amenable for HBV infection and disease development. The roadmap will be published as review article/opinion piece.
The full programme can be found below and printed here.
|ICE-HBV welcome and introductions||T. Jake Liang||8:30-8:40|
|What we learned about HBV pathogenesis and immune intervention in chimpanzees, woodchucks and immunocompetent transgenic mice||Luca G. Guidotti||8-40-9:15|
|Comparison of the Adeno-HBV, the AAV-HBV and the HBVtg mouse models||Ulla Protzer||9:15-9:50|
|Hydrodynamic injection mouse model||Pei-Jer Chen||10:05-10:25|
|Mouse models based on stem cell derived hepatocytes/FAH||Alexander Ploss||10:25-10:45|
|Human liver chimeric mice and their application for drug assessment||Maura Dandri||10:45-11:20|
|Liver and immune system humanized mouse models to study pathophysiology and therapeutics.||Hélène Strick Marchand
|11:20 – 11:55|
|Mouse with humanized NTCP||Wenhui Li||13:00-13:20|
|Towards a mouse model susceptible to HBV infection – overcoming the barrier to cccDNA formation.||Jianming Hu||13:20-13:35|
|Macaque with human NTCP for HBV infection||Ben Burwitz||13:35-13:55|
|Industry perspective in most wanted features for HBV animal models||Scott Balsitis||13:55-14:30|
|Panel Discussion (facilitation by T. Jake Liang)||All speakers||14:30-15:10|
|Closing||Hélène Strick Marchand & Wenhui Li||15h10-15h30|